Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

1 Sept 2015Annals of Oncology

DOI : 10.1093/annonc/mdv268

Authors

J. Guigay, J. Fayette, A.F. Dillies, C. Sire, J.N. Kerger, I. Tennevet, J.P. Machiels, S. Zanetta, Y. Pointreau, L. Bozec Le Moal, S. Henry, A. Schilf, J. Bourhis